Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207849 | 0.91 | TDP1 (0.40) | TDP1MAPK1EPHX2PDK2HPGD | |
| SCHEMBL3614168 | 0.88 | FDPS (0.43) | TDP1MAPK1EPHX2PDK2HPGD | |
| SCHEMBL5704638 | 0.82 | KCNA3 (0.42) | TDP1MAPK1 | |
| SCHEMBL17134208 | 0.82 | KCNA3 (0.33) | TDP1 | |
| SCHEMBL161036 | 0.81 | LMNA (0.41) | PDK2NR1H4HPGD | |
| SCHEMBL129009 | 0.79 | KMT2A (0.42) | MAPK1HPGD | |
| SCHEMBL8695255 | 0.79 | KCNA3 (0.39) | SIGMAR1 | |
| SCHEMBL9113470 | 0.78 | KCNA3 (0.38) | TDP1MAPK1GAA | |
| SCHEMBL7455578 | 0.78 | SIGMAR1 (0.45) | TDP1SIGMAR1 | |
| SCHEMBL517096 | 0.78 | PKM (0.38) | MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106232120-B | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2- (1H) -ones | 爱尔皮奥治疗有限公司 | 2021-01-08 | — | — | CN | claimed |
| EP-3400231-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | Technion Research & Development Foundation Limited (IL) | 2018-11-14 | — | — | EP | claimed |
| EP-3344641-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | Eloxx Pharmaceuticals Ltd. (IL) | 2018-07-11 | — | — | EP | claimed |
| WO-2017118967-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-07-13 | — | — | WO | claimed |
| WO-2017037719-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2017-03-09 | — | — | WO | claimed |
| EP-3107542-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | Aerpio Therapeutics, Inc. (US) | 2016-12-28 | — | — | EP | claimed |
| US-9388135-B2 | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones | AERPIO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | claimed |
| WO-2015126860-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. | 2015-08-20 | — | — | US | claimed |
| CN-101812033-A | Ibuprofen 2-arylmorpholine ethyl ester as well as preparation method and application thereof | UNIV HUNAN | 2010-08-25 | — | — | CN | claimed |
| CN-101812058-A | Indometacin 2-arylmorpholine ethyl, preparation method and application thereof | UNIV HUNAN | 2010-08-25 | — | — | CN | claimed |
| CN-110997689-B | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230181612-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-06-15 | — | — | US | disclosed |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-03-28 | — | — | US | disclosed |
| CN-114957357-A | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2008126684-A2 | AGRICULTURAL COMPOSITION FOR CONTROLLING OR PREVENTING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-23 | — | — | WO | disclosed |
| US-6893650-B1 | N2-phenylamidine derivatives | BAYER CROPSCIENCE GMBH (DE) | 2005-05-17 | — | — | US | disclosed |
| CN-1170813-C | N2 phenylamidine derivatives | �ݶ�ũ������˾ | 2004-10-13 | — | — | CN | disclosed |
| CN-1342137-A | N2 phenylamidine derivatives | AFINDY AGRICULTURAL SCIENCES G (DE) | 2002-03-27 | — | — | CN | disclosed |
| US-4173630-A | N2 Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | CYP4B1, CYP8B1, HPD | TDP1 3373/4885MAPK1 2056/4885EPHX2 334/4885 |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | TDP1 1548/4885MAPK1 3549/4885EPHX2 4258/4885 |
| US-20230181612-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, NSUN3, AARS1 | TDP1 1936/4885MAPK1 2997/4885EPHX2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.